Loading clinical trials...
Loading clinical trials...
The combination of programmed death receptor 1 (PD-1) inhibitors with chemotherapy has been recognized for the treatment of advanced and metastatic esophageal squamous cell carcinoma (ESCC). To the be...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Ye jinjun
NCT07463573 · Esophageal Squamous Cell Carcinoma (ESCC)
NCT07359417 · Esophageal Squamous Cell Carcinoma (ESCC), Esophageal Cancer, Squamous Cell
NCT05473156 · Locally Advanced or Metastatic Solid Tumors, Non Small Cell Lung Cancer (NSCLC), and more
NCT06709417 · Esophageal Squamous Cell Carcinoma (ESCC)
NCT06710665 · Esophageal Squamous Cell Carcinoma (ESCC)
Jiangsu Provincial Cancer Hospital
Nanjing, Jiangsu
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions